An injection of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) Taken together, our results demonstrate that HP-β-CD works in cells of Npc1 -/-mice by rapidly liberating lysosomal cholesterol for normal sterol processing within the cytosolic compartment.
Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides composed of 6, 7, or 8 glucopyranosides, which are called α, β, or γ-CD, respectively. CDs have a distinctive barrel configuration with a hydrophilic exterior promoting water-solubility and a hydrophobic interior that accommodates small lipophilic molecules. Both of these properties make CDs ideal vehicles to increase the solubility of hydrophobic drugs; thus CDs have been approved by the Food and Drug Administration (FDA) as delivery agents (1) (2) (3) (4) . In addition to natural CDs that are products of starch, several modified forms of β-CD have been synthesized including 2-hydroxypropyl (HP-β-CD) and sulfobutylether (SBE-β-CD), which have less toxic effects in vivo. These CDs were considered to possess no therapeutic potential and were thought to simply serve as benign carriers of lipophilic drugs, which could be released into the bloodstream allowing CDs to be excreted intact separately through the kidneys (3) . That is until 2009, when it was reported that a single injection of HP-β-CD led to dramatic improvements in cholesterol homeostasis, inflammation, and lifespan in the mouse model for the lysosomal storage disease, Niemann Pick Type C (NPC) (5) .
NPC disease is a rare autosomal recessive disorder in which inactivating mutations in either NPC1 or NPC2 genes result in aberrant intracellular transport of unesterified cholesterol from the late endosome/lysosome (LE/L) and massive lipid accumulation within this compartment in all cells (6, 7) . NPC disease presents as hepatic dysfunction, splenomegaly, pulmonary disease, and neurodegeneration resulting in premature death, which typically occurs 4 as a model to test potential therapies. Therefore when HP-β-CD was shown to extend the lifespan of Npc1 -/-mice to 118d with a single injection to 7-day-old pups (5) , it quickly became a major focus of the NPC research community.
Since the initial studies in mice, HP-β-CD therapy has been also shown to be effective in the Npc1 -/-cat model (10) and a NIH-sponsored clinical trial to test HP-β-CD efficacy in humans is being organized (http://nctt.nih.gov/2754421). Additionally, much research has been undertaken to further understand how CD is working in Npc1 -/-animal models. Notably, serial injections of HP-β-CD were shown to double the lifespan of the Npc1 -/-mouse (11, 12) , and continuous intrathecal administration was found to dramatically rescue Purkinje cell loss within the cerebellum (13) . HP-β-CD does not require a functional NPC1 or NPC2 protein to work as suggested by studies using cell culture models (14-16) and confirmed in mice when HP-β-CD was shown to significantly decrease hepatic cholesterol synthesis rates in Npc1
Npc2
-/-, and rare
Npc1
-/-
Npc2
-/-double-knockout mice (17) . Studies performed within a variety of tissues harvested 24h after a single HP-β-CD injection to 7-or 49-day-old Npc1 -/-mice have shown dramatic changes in sterol dynamics, including: a decrease in cholesterol synthesis rates; an increase in the ratio of esterified/unesterified cholesterol; down-regulation of the sterol regulatory element-binding protein 2 (SREBP2) and its target genes; and increased expression of liver X receptor (LXR) target genes (5, 18) . These measurable shifts in sterol homeostasis serve as surrogate markers to indicate that the cell is responding to a state of cytosolic cholesterol excess. Since these changes were observed after HP-β-CD administration to Npc1 -/-mice only and not seen for wildtype mice, they further suggest that the excess unesterified cholesterol is being released from the LE/L compartment in Npc1 -/-mice. Overall these data suggest that HP-β- 5 CD is able to facilitate the release of the lysosomal pool of unesterified cholesterol from NPCdeficient cells within 24h.
Although virtually all studies thus far have been performed 24h after HP-β-CD, a single time course experiment using [ 14 C]-radiolabelled HP-β-CD in 49-day-old mice demonstrated that it is cleared from plasma within 3h and from the whole body within 6h after a subcutaneous (sc) dose of 4,000 mg/kg body weight (mpk) (18) . Therefore, we performed a series of studies in
Npc1
-/-mice to evaluate the time course of changes elicited by HP-β-CD, 1-12h after administration, to further understand its mechanism of action. The experiments were designed: 1)
to measure the rate of change in lipid balance and corresponding mRNA levels; 2) to determine whether a CD/cholesterol complex is evident at any time in plasma or urine; 3) to evaluate how rapidly inflammation is reduced; 4) to assess the direct effects of HP-β-CD and SBE-β-CD on primary cells (neurons and macrophages) in culture. Together, these studies provide novel insights into the mechanism by which HP-β-CD frees trapped unesterified cholesterol from the LE/L of cells lacking NPC1. at 4,000 mpk or vehicle (saline at equivalent volume of 20 μl/g body weight (bw)). When mice were used as a source of cells for culture, macrophages were obtained from 2-month-old mice, and hippocampal neurons were harvested from 1-day-old pups. As no differences in response to HP-β-CD were evident between male and female mice in our previous reports (5, 9, 12, 13, 17, 18) , these studies utilized either equal numbers of males and females per group (Figs. 1, 4D Tissue cholesterol concentration. The aliquots of liver and spleen in KOH used for the synthesis determination were also used to measure total cholesterol content. Briefly, the cholesterol was extracted and quantified by gas chromatography (GC) with a stigmastanol internal standard as previously described (21) . The total cholesterol concentration of each organ is expressed as the mg of cholesterol per gram of tissue.
Unesterified/esterified cholesterol determination. From a different cohort of mice, livers were flash frozen and were crushed into a powder, which was weighed and solubilized in a 2:1 chloroform to methanol solution for lipid extraction. Free and esterified cholesterol were separated using a silica column (Sep-Pak Vac RC; Waters Corp., Milford, MA) and were quantified by GC as previously described (22) . The cholesterol concentration of each organ is reported as the mg of unesterified cholesterol or cholesteryl ester per gram of tissue. 8 or Zeitgeber time (ZT) 9). Equal volumes of plasma/mouse were pooled for similarly treated animals (n=2/group) and samples were provided to a core facility where lipoprotein profiles were obtained using fast protein liquid chromatography (FPLC) as described previously (23) . Total cholesterol concentrations in eluted fractions were measured using both an enzyme-based method (Infinity Cholesterol Reagent, Sigma) and by solvent extraction followed with measurement by GC (see above). No differences were found between the two methods, so only values from the enzyme-based method, expressed as µg of total cholesterol per fraction, are reported.
Urine cholesterol concentration.
After receiving an injection of saline or HP-β-CD before lights out (ZT 10), a separate cohort of mice were individually housed in metabolic chambers in a maintained animal facility to collect urine for the following 48h. While in the chamber, mice were allowed ad libitum access to food and water. Urine collections were spun at 1x10 4 x g for 5 min at 4°C, and the supernantants were stored at 4°C. Later, the samples was dried down and then saponified in alcoholic KOH. Total cholesterol was extracted and measured by GC as described above. The cholesterol content of each urine sample is reported as the μg of total cholesterol per 24h.
Relative mRNA levels
Tissues. Npc1 +/+ or Npc1 -/-mice (n=4 mice/group) were given a single sc injection of HP-9 until total RNA was isolated using RNA STAT-60 (Tel-Test, Inc.). RNA concentrations were determined by absorbance at 260 nm with a Thermo Scientific Nanodrop 100
Spectrophotometer. RNA was treated with RNase-free DNase (Roche) and converted to cDNA using SuperScript II reverse transcriptase (Invitrogen) as previously described (23, 24 µM Ara-C (Sigma, to reduce astrocyte contamination) in DMEM supplemented with 2 mM Lglutamine. On culture day 8, cells were provided fresh media containing vehicle or treatment and then harvested for RNA using the experimental designs described above for macrophage cultures.
Measurement of plasma cytokine concentrations
For the 0h time point, 60 µL of blood was harvested from the tail vein of Npc1 +/+ or
Npc1
-/-mice. The mice were allowed to recover for 1 day, and then mice were injected with HP-β-CD or saline. Then 3, 6, 12, and 24h later, another 60 µL aliquot of blood was harvested from the tail. Each tail-blood isolation was collected into a tube with 3 µL of 0.5 M EDTA on ice.
Blood was spun down at 1x10flash frozen in liquid nitrogen, and stored at -80°C until analyses for cytokine levels were performed. 10 µL of each sample was analyzed in duplicate, alongside standard curves, on a 7-plex ultra-sensitive pro-inflammatory mouse cytokine plate (#K11012C-1, MesoScale Discovery, Gaithersburg, Maryland) according to the manufacturer's instructions. The plate was read using a SECTOR® Imager 6000 instrument (MesoScale Discovery). Concentrations for IFNγ, IL-1β, IL-6, IL-10, IL-12p70, KC/GRO, and TNF are reported as pg of protein per mL of plasma.
Data Analysis
All data are presented as the mean ± SEM. Statistically significant differences (P-value <0.05) between the Npc1 +/+ controls and the 0h CD or saline-treated Npc1 -/-group were tested using an unpaired Student's t-test and are represented by ╪ .
Significant differences between

Npc1
-/-mice studied 0h after CD treatment and those studied at later time points were determined using a one-way ANOVA followed by Dunnett's post-hoc analysis and are represented by * (P <0.05) to *** (P <0.0005). All statistical tests were performed using GraphPad Prism5 software (GraphPad Software, Inc. San Diego, CA).
RESULTS
De novo cholesterol synthesis rates are reduced in Npc1 -/-mice 3h after HP-β-CD injection
As HP-β-CD is cleared within 3 to 6h from the plasma and total body of 49-day-old mice (18) , it is likely that HP-β-CD exerts its effect(s) on Npc1 -/-mice during this timeframe. To test this, 49-day-old Npc1 -/-mice were given a single dose of HP-β-CD, and indices of sterol balance were characterized 0 to 12h later. Significant increases in organ weights, tissue total cholesterol content, and cholesterol synthesis rates in Npc1 -/-mice compared to their wildtype littermates were evident at the outset (0h) of this study ( Fig. 1) , which are consistent with previous reports (28) . Over the course of these 12h studies, the single dose of HP-β-CD caused no differences in organ weights or total cholesterol concentrations in liver and spleen of Npc1 -/-mice ( Fig. 1A-D ).
However, a significant decrease in cholesterol synthesis rates in these tissues was evident within 3h of the HP-β-CD injection ( Fig. 1E-F) . By 6h after HP-β-CD administration, hepatic cholesterol synthesis rates in Npc1 -/-mice leveled off at a rate of 197 nmol/g/h and then remained steady for the duration of the 12h study (Fig. 1E ). This was a reduction of ~80% compared to the initial rate (Npc1 -/-0h, 1010 nmol/g/h) in liver and was even less than that measured in Npc1 +/+ mice (580 nmol/g/h). A similar timeframe of change was observed in sterol synthesis rates from spleen of Npc1 -/-mice after HP-β-CD administration; although, the absolute rates of cholesterol synthesis were much lower compared to liver (Fig. 1F) .
Hepatic cholesteryl ester content is increased in Npc1 -/-mice 3h after HP-β-CD injection
Although there was no measurable change in total cholesterol content within the first 12h
after HP-β-CD injection in Npc1 -/-mice ( Fig. 1C) , the relative quantities of unesterified cholesterol (largely representing cholesterol sequestered within the LE/L in the Npc1 -/-model) and cholesteryl ester were measured in liver. A modest, albeit not statistically significant decrease in hepatic unesterified cholesterol from 20.5 mg/g at 0h to 17.1mg/g ( Fig. 2A ) was observed 12h after HP-β-CD injection in Npc1 -/-mice. In contrast, hepatic cholesteryl ester concentrations in Npc1 -/-mice were significantly increased at 3h after HP-β-CD injection and reached a plateau by 6h (Fig. 2B) . The rate of change observed in cholesteryl ester content after HP-β-CD administration is consistent with that observed for cholesterol synthesis (Fig. 1E-F ).
Significant changes in mRNA levels are observed 6h after HP-β-CD injection
To identify molecular mechanisms that could account for the changes in cholesterol balance measured in Npc1 -/-mice just 3h after HP-β-CD administration, mRNA levels for cholesterol-related genes were measured. Previously, significant increases in the expression of target genes for the oxysterol-responsive nuclear hormone receptor, LXR, and decreases in the mRNA levels of genes regulated by the sterol-sensing transcription factor, SREBP2, were reported 24h after HP-β-CD treatment in Npc1 -/-mice (5). These observed mRNA changes are consistent with an increase of intracellular sterol, which would reduce de novo cholesterol synthesis via SREBP2 and enhance cholesterol efflux and catabolism via LXR. As shown in and Reductase (Hmg CoA Red), are significantly reduced 6h after HP-β-CD by >85% compared to Npc1 -/-mice at 0h to levels even lower than those measured in Npc1 +/+ mice (Fig. 2C, E) . A decrease in the mRNA levels of Srebp2 and its target genes are also seen in spleen and ileum as early as 3h after HP-β-CD treatment in Npc1 -/-mice ( Fig 3A, B) ; although, the reduction observed in these tissues was not as profound as in liver. It is noteworthy that initial changes in sterol synthesis rates ( Fig. 1) occurred at or before the changes in mRNA levels of the ratelimiting enzyme Hmg CoA Red (Fig. 2) , which is consistent with rapid sterol-sensing mechanisms involving post-translational modifications that affect HMG CoA RED protein stability and activity (reviewed in (29)).
Cholesterol 7α-hydroxylase (Cyp7a1), the LXR target gene in mice, is a rate-limiting enzyme for conversion of cholesterol to bile acids in liver. It should be noted that hepatic
Cyp7a1 mRNA levels exhibit a pronounced circadian rhythm (30); thus, our study design utilized staggered HP-β-CD injection times to limit tissue harvesting to a single time of day (ZT 9). Cyp7a1 mRNA levels were reduced by 50% in Npc1 -/-mice compared to Npc1 +/+ littermates.
In Npc1 -/-mice, HP-β-CD administration resulted in increased Cyp7a1 mRNA levels with a trend observed as early as 6h and a significant increase (3-fold) evident at 12h (Fig. 2D) . The mRNA level of ATP-binding cassette transporter a1 (Abca1), another LXR target gene, was found to be only transiently increased in livers of Npc1 -/-mice at 6h after HP-β-CD (Fig. 2F) . These results from liver are in contrast to Abca1 mRNA levels in spleen (Fig. 3C) , where Abca1 expression was dramatically increased by 3h (2.8-fold) after HP-β-CD in Npc1 -/-mice and remained at this level throughout the 12h study. This Abca1 expression difference between tissues can likely be explained by the fact that Abca1 is not an LXR target gene in hepatocytes, where a distinct To measure total plasma cholesterol, FPLC gel filtration for fractionation of lipoproteins was performed on pooled plasma samples (Fig. 4) . First, lipoprotein profiles of Npc1 +/+ and Npc1 -/-mice were compared, and it was observed that plasma HDL cholesterol content (represented by fractions 23-35, Fig. 4A ) is significantly greater in Npc1 -/-mice, consistent with a previous report (32) . During the first 3h after injection when HP-β-CD is still present in the plasma, there were no apparent changes in the total plasma lipoprotein cholesterol levels of
Npc1
-/-mice (Fig. 4B) . Likewise, at time points (6h and 12h) when changes in sterol balance are underway yet HP-β-CD is no longer detectable in the whole animal, there was no evidence of altered total cholesterol content of any lipoprotein fractions in plasma from Npc1 -/-mice ( HP-β-CD is excreted intact into urine (3), thus urine was collected for 48h after HP-β-CD administration to determine whether cholesterol was present as a complex with excreted CD (Fig. 4D) (Fig. 5A) , and similar elevations were observed for selected cytokines in other organs (spleen, Fig. 5E and ileum, Fig, 5F ). 24h after a single injection of HP-β-CD, the mRNA levels of elevated inflammation markers in Npc1 -/-liver were significantly reduced (Fig. 5A) , and comparable changes were observed for the hepatic protein levels of IFN-γ, CXCL1, and TNFα (data not shown). These findings were extended to determine whether plasma levels of these cytokines were similarly affected in Npc1 -/-mice and if they could potentially serve as biomarkers to follow NPC disease progression and/or efficacy of novel therapies. While the mRNA levels of Il-12p40, Ifn-γ, Cxcl1, and Tnfα were much higher in the livers of Npc1 -/-mice and reduced with HP-β-CD treatment (Fig. 5A) , these changes were not mirrored by the circulating protein levels of these cytokines in mouse plasma (Fig. 5B) . A significant increase was only observed for plasma IL-6 levels 24h after HP-β-CD injection of Npc1 -/-mice; however, this increase was also evident in Npc1 +/+ injected with saline (HP-β-CD) and Npc1 -/-injected with saline (vehicle) (Supplementary Fig. 1 ).
As nearly all cytokine mRNA levels were reduced by 24h after HP-β-CD administration to Npc1 -/-mice (Fig. 5A) , the time course of this HP-β-CD effect was evaluated in several tissues for which a representative set of mRNA levels is provided (Fig. 5C-F) . There was a trend towards decreased mRNA levels of Tnfα in liver following HP-β-CD administration, which reached significance by 12h (Fig. 5C) . There was no change in Mip1α mRNA levels in liver or spleen by 12h (Fig. 5D-E) ; however, a significant decrease in Mip1α mRNA in ileum was observed as early as 6h (Fig. 5F ). In summary, changes in cytokine expression in tissues of
-/-mice were absent or modest during the first 12h after HP-β-CD despite dramatic reductions in mRNA and protein levels in liver by 24h, suggesting that the anti-inflammatory effects of HP-β-CD are secondary to changes in sterol homeostasis.
Significant changes in mRNA levels are observed in Npc1 -/-cells treated with HP-β-CD and
SBE-β-CD in culture:
In the adult mouse, a single sc injection of HP-β-CD at 4,000 mpk is estimated to provide a maximal plasma concentration of 1.3 mM (18) . To confirm the acute changes observed for sterol balance and sterol-associated gene expression in vivo, a relevant concentration range of HP-β-CD (0.3-1.5 mM) was applied in vitro to primary neurons and macrophages cultured from
Npc1
+/+ and Npc1 -/-mice (Fig. 6) . As observed in whole animals, administration of HP-β-CD had virtually no effect in wildtype cultured cells. However, after only 4h of exposure, gene expression changes consistent with an increase in intracellular sterol were observed in Npc1 -/-cells. Representative LXR target genes, Idol in macrophages (Fig. 6A) and Abcg1 in neurons (Fig. 6B) , exhibited a dose-dependent increase in mRNA level; while the mRNA levels of selected SREBP2 target genes, Hmg CoA Syn (Fig. 6C) and low density lipoprotein receptor (Ldlr) (Fig. 6D) , were maximally reduced with the minimal dose of 0.3 mM HP-β-CD. While the reduction in Hmg CoA Syn mRNA levels did not reach significance in macrophage, the decrease in Ldlr was statistically different between the vehicle and HP-β-CD treated Npc1 -/-neurons.
The ability of various cyclodextrins to interact, adsorb, and ultimately extract unesterified cholesterol from lipid membranes into an aqueous environment has been extensively studied (2,
16, 36-40). Single β-CDs can accommodate an unesterified cholesterol in their hydrophobic
pocket, but about one-third of the sterol molecule is expected to protrude from the CD (36, 40) .
In this 1:1 configuration, all β-CDs appear capable of facilitating the translocation of free cholesterol between apposing membranes (or between donor and acceptor lipid vesicles) -thus behaving like a "shuttle". To fully extract unesterified cholesterol from lipid membranes, β-CDs must form a 2:1 complex to allow for solubilization of the sterol into an aqueous environment (2) -thus acting as a "sink". HP-β-CD can form such a 2:1 complex; whereas, sulfobutylether-β-CD (SBE-β-CD), which harbors chemical modifications that sterically hinder it from dimerization (2, 41), can not form the requisite 2:1 complex with cholesterol and fails to solubilize cholesterol. In order to determine whether a sink/solubilizing function of HP-β-CD is essential to its mechanism of action in Npc1 -/-cells, the effects of HP-β-CD and SBE-β-CD were compared in vitro, using the concentration of 0.3 mM and the readout of altered gene expression established in our previous studies (Fig. 6, Fig 2&3) . Both forms of β-CD lead to near equivalent reductions in
Hmg CoA Syn and Ldlr mRNA levels in macrophages (Fig. 7 A, C) . In addition, SBE-β-CD and
HP-β-CD exhibited comparable efficacy in inducing the LXR target gene, Abcg1, and decreasing
Ldlr mRNA in neurons (Fig. 7 B, D) . Neither HP-β-CD nor SBE-β-CD treatment had any effect of Npc1 +/+ cells. Thus, these cell-based studies demonstrate a cell-autonomous activity of β-CDs, and further support a mechanism of action that does not rely on the ability of cyclodextrins to solubilize cholesterol into an aqueous environment.
DISCUSSION
Niemann-Pick type C disease is a rather unique lysosomal storage disorder, because the protein products of mutated genes, NPC1 or NPC2, do not harbor enzymatic activity. Rather, NPC1, a large integral protein of the lysosomal membrane, and NPC2, a small soluble protein localized to the lumen of the LE/L, work in tandem to translocate LDL-derived cholesterol from the lyosomal compartment into the cytosol of cells (42, 43 (5) demonstrating that a single injection of HP-β-CD extended the lifespan of young Npc1 -/-mice by greater than 35% and subsequent studies (11, 12, 18) showing that repeated injections increased longevity by nearly two-fold, pointed to this agent as a novel therapy for NPC patients.
CDs are membrane-impermeant oligosaccharides that have been extensively used by cell biologists to manipulate cholesterol content and trafficking in cultured cells (38) . In elegant studies by Rothblat and colleagues (36, 37) , HP-β-CD addition, at concentrations exceeding 1 mM, to the media of cultured cells acted as a cholesterol "sink" resulted in the rapid efflux of Using cell culture studies of neurons and macrophages isolated from wildtype and Npc1 -/-mice, a 4h exposure to increasing concentrations of HP-β-CD (ranging from 0-1.5 mM) had virtually no effect on wildtype cells, but caused altered gene expression consistent with sterol release from the LE/L into the cytosol of cells lacking NPC1 function (Fig. 6) . A CD-facilitated egress of lysosomal sterol would be predicted to reduce processing of SREBP2 and decrease expression of its target genes, including Hmg CoA Syn and Ldlr. In addition, this flux of sterol from lysosome to cytosol/nucleus would increase the expression of LXR target genes, such as
Idol and Abcg1. These findings are consistent with the recent report of Peake and Vance (50) demonstrating the reduction of lysosomal sterol and increase of cellular cholesteryl ester in cultured Npc1 -/-neurons, astrocytes, and microglia treated with HP-β-CD. The cytotoxic effects they observed for high-dose HP-β-CD, which were not observed in our studies, were likely the result of longer incubation times and the absence of serum in their culture conditions.
In our subsequent comparison of HP-β-CD (which can act as "shuttle" or "sink") against SBE-β-CD (which can function only as "shuttle"), similar changes in sterol-responsive gene expression were obtained for these two CDs, but only in Npc1 -/-cells (Fig. 7) . Thus, it can be concluded that under these culture conditions and CD concentrations, β-CD is not acting as an extracellular "sink" to extract/solubilize plasma membrane cholesterol, a mechanism that should affect cholesterol dynamics of both control and mutant cells. In addition, the similar behaviors of HP-β-CD and SBE-β-CD to elicit changes in intracellular sterol revealed by altered gene expression, suggest that only the "shuttle" capacity of CD is required. This scenario is consistent with proposals that CD is promoting the translocation of unesterfied cholesterol from internal membranes of the LE/L across the limiting lysosomal membrane (16, 17) for egress into the cytosolic compartment of Npc1 -/-cells.
A subcutaneous injection of HP-β-CD at 4,000 mpk to mice is estimated to result in maximal plasma levels of ~1.3 mM (18) with a systemic half-life of ~1.6h (13) . Within 4h, greater than 90% of a CD dose is eliminated intact by urinary excretion from rats (51) . Based on these observations, we elected to evaluate the temporal changes in sterol homeostasis and the fates of CD and sterol in Npc1 -/-mice injected with HP-β-CD (summarized in Supplemental   Fig. 2 ). The first significant changes observed were a pronounced decrease in sterol synthesis rates in liver and other organs ( Fig. 1) and an increase in hepatic cholesteryl ester (Fig. 2B) . By 3h after injection, sterol synthesis rates were reduced by half and reached a plateau at 6h that was maintained for the duration of these 12h studies (at a level ~20% of 0h Npc1 -/-and below that of wildtype mice). At 6h and 12h after injection, changes in the expression of genes associated with altered cellular sterol balance were evident ( Fig. 2 and 3 ). This sequence of changes is consistent with CD-mediated lysosomal cholesterol release to first affect post-translation mechanisms reducing sterol synthesis rates (via regulation of HMG CoA Red stability) and increasing formation of cholesteryl ester via ACAT activity, and to secondly modulate transcriptional processes regulated by SREBP2 and LXR.
During this timeframe, there was no evidence of increased cellular efflux of sterol either to alter the cholesterol content of circulating lipoproteins (Fig. 4B, C) or as a CD-cholesterol complex in plasma or urine (Fig. 4B, C, D) . Our methods were able to accurately detect significant but subtle increases (in the ug range) in the level of cholesterol within urine and plasma in Npc1 -/-mice compared with Npc1 +/+ mice. Therefore, if a change had occurred after HP-β-CD to alter the level of cholesterol in plasma or urine, it would have been easily ascertained through our analyses. Thus, the breadth of these studies suggest that HP-β-CD acts within Npc1 -/-cells, as a shuttle to facilitate the egress of lysosomal unesterfied cholesterol to intracellular membrane or protein acceptors, without serving as a sink to facilitate cholesterol transport and elimination via plasma and/or urine.
Finally, all agents that have been identified to extend the lifespan of Npc1 -/-mice have decreased expression of proinflammatory cytokines in virtually every tissue measured (5, 12, 34, 35, 47) . Therefore, we included this readout in our time-course studies of HP-β-CD. 24h after injection of HP-β-CD, mRNA levels ( Fig. 5) for Tnfα, Mip-1α, and other markers of increased macrophage number and activation were significantly reduced in tissues of Npc1 -/-mice.
However, these changes were for the most part not observed within 12h of HP-β-CD administration, suggesting that they occur after changes in sterol homeostasis. And importantly, although tissue RNAs and proteins were altered, circulating cytokine levels were neither elevated in the Npc1 -/-mice, nor affected to a significant degree by CD treatment ( 
